Top View
- Tyrosine Kinase Inhibitor (TKI) Flow Chart for the Treatment Of
- Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
- The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce
- Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
- Clinical Pharmacokinetics of Imatinib Mesylate
- Nilotinib Vs Imatinib in Patients with Newly Diagnosed
- Comparative Pharmacology of Tyrosine Kinase Inhibitors for The
- (Vismodegib) for Gleevec
- Axitinib and Sorafenib Are Potent in Tyrosine Kinase Inhibitor Resistant
- Appendix B - Product Name Sorted by Applicant
- Intolerant Patients with Chronic Myeloid Leukemia in Blastic Phase
- Effect of Tyrosine Kinase Inhibitors on Renal Handling of Creatinine By
- Histological Changes of the Rat Liver After Administration of Imatinib Mesylate:An Experimental Study
- Cumulative Mechanism of Several Major Imatinib-Resistant Mutations in Abl Kinase
- Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
- 1. Composition Amitriptyline Hydrochloride IP 10Mg Propranolol
- Effect of Imatinib on the Biochemical Parameters of the Reproductive Function in Male Swiss Albino Mice
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Gynecomastia in a Male After Dasatinib Treatment for Chronic Myeloid Leukemia
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Assessment of Vitamin D Levels in Newly Diagnosed Breast Cancer
- Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
- Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk
- About OMICS Group
- Tasigna (Nilotinib) Capsules Label
- Highlights of Prescribing Information
- And Nilotinib Drug Interactions with the Tyrosine Kinase Inhibitors Imatinib
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Durable Response with a Combination of Imatinib and Sorafenib in KIT Exon 17 Mutant Gastrointestinal Stromal Tumor
- Safety of Topical Neuromodulators for the Treatment of Pruritus
- Tyrosine Kinase Inhibitors in Veterinary Medicine
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- Selective Tyrosine Kinase Inhibition by Imatinib Mesylate for the Treatment of Autoimmune Arthritis Ricardo T
- Tyrosine Kinase Inhibitors - Oral
- Transforming Into Oncology- Sunao Manabe President and COO June 2, 2019 ASCO Investor Relations Presentation, Chicago, IL Forward-Looking Statements
- Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages
- Bcr-Abl Tyrosine Kinase Inhibitor Imatinib As a Potential Drug for COVID-19
- Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans
- Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
- Oral Targeted Therapy for Cancer
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- SPRYCEL (Dasatinib) Tablets Label
- Glivec, INN-Imatinib
- Second Generation Tyrosine Kinase Inhibitors for the Treatment of Chronic Myelogenous Leukaemia with Intolerance of Hematologic Resistance to Imatinib
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Emtansine (T-DM1) Resistance in HER2-Positive Cancer
- Dasatinib Vs. Imatinib in Patients with Chronic Myeloid Leukemia
- GLEEVEC® (Imatinib Mesylate) Tablets Label
- Gastrointestinal Stromal Tumors (Gists): Novel Therapeutic Strategies with Immunotherapy and Small Molecules
- Effects of Combined Admistration of Imatinib and Sorafenib in a Murine
- In HER2-Positive Breast Cancer Cells
- Tyrosine Kinase Inhibitor-Induced Macrocytosis
- Living Well with Chronic Myeloid Leukaemia (CML)
- Metabolic N-Dealkylation and N-Oxidation As Elucidators of the Role of Alkylamino Moieties in Drugs Acting at Various Receptors
- A New Therapeutic Option for Advanced Gastrointestinal Stromal Tumors
- Publication Agenda CHMP 07-10 December 2020
- Sprycel, INN-Dasatinib
- Alternating Or Combined Therapy with Axitinib and Bosutinib for Patients with Chronic Myeloid Leukemia in Chronic, Accelerated Or Blastic Phases 2015-0787
- Thyroid Effects of Tyrosine Kinase Inhibitors
- Tyrosine Kinase Inhibitor Associated Vascular Toxicity in Chronic Myeloid